Cross Country Healthcare revenues fall in Q4
Cross Country Healthcare net loss was $6m, compared to a net income of $398,000 for the same period in 2009. For the full year of 2010, the company
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.